Seer, Inc.'s SEC filings document material events, operating results, securityholder rights and governance matters for a Nasdaq-listed life sciences company focused on research-use proteomics. Recent 8-K reports cover results of operations and financial condition, material definitive agreements, modifications to securityholder rights, other events and related exhibits.
The filings disclose Seer's Class A common stock, Preferred Stock Purchase Rights, Tax Benefit Preservation Plan for net operating loss and other tax attributes, amendments to that plan, and the completed conversion of Class B common stock into Class A common stock. They also record board and shareholder matters, leadership appointments, and intellectual-property updates related to the Proteograph Product Suite and particle-based protein enrichment.
Seer, Inc. filed an initial insider ownership report for Chief Commercial Officer Anthony R. Bazarko. This Form 3 does not list any specific share transactions or derivative positions and serves as a baseline disclosure of his status as an officer subject to insider reporting rules.
Seer, Inc. has appointed Anthony Bazarko as its new Chief Commercial Officer. He brings more than two decades of commercial leadership experience across life sciences, diagnostics, and biotechnology, including prior roles as President and CEO of Biologos and Chief Commercial Officer at Specific Diagnostics.
At Seer, Bazarko will lead Sales, Marketing and Customer Experience to strengthen commercial execution and support the next phase of growth for the Proteograph® Product Suite. Seer highlights his track record in driving revenue growth, building high-performing teams, and leading global go-to-market strategies.
Invus Public Equities and related entities filed an Amendment No. 4 to Schedule 13G/A reporting beneficial ownership of 2,458,673 shares of Seer, Inc. Class A common stock as of March 31, 2026. The filing states this equals 4.4% of the class based on 56,420,772 shares outstanding as of February 23, 2026. The cover lists affiliated reporting persons — Invus Public Equities, Invus PE Advisors, Invus Global Management, Siren, L.L.C., and Raymond Debbane — and describes control relationships that could cause each to be deemed the beneficial owner. The filing certifies the shares were not acquired to change or influence control.
Seer, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add the Part III sections on directors, governance and executive compensation. The filing details a seven‑member board, of which five are Nasdaq‑defined independent directors, and describes committee structures and meeting activity.
Non‑employee director pay combines cash retainers and equity, with standard annual cash fees of $42,500 for board service and additional amounts for committee and lead roles. The amendment also outlines 2025 compensation and outstanding equity awards for the CEO and President/CFO, along with severance and change‑in‑control protections and equity plan features.
Seer, Inc. reported that its Board of Directors unanimously rejected a revised unsolicited, non-binding proposal from the Radoff-JEC Group to acquire all outstanding Class A common stock for $2.35 per share in cash plus a contingent value right.
The Board, after consulting independent financial and legal advisors, determined the proposal significantly undervalues Seer, noting that the implied equity value is below the company’s current cash, cash equivalents and investments and does not reflect the value of its proteomics platform or growth prospects.
Seer highlights adoption of its Proteograph Product Suite, selection for Singapore’s SGK100 study, more than 80 peer-reviewed publications, and 240 worldwide patents (including 82 issued) as evidence of its strategic position. The company also disclosed it will file a definitive proxy statement and send a BLUE proxy card for its 2026 Annual Meeting.
Seer, Inc.: Activist group files preliminary proxy materials and an acquisition proposal. Bradley L. Radoff, Michael Torok and affiliated participants (the "Radoff-JEC Group") say they own approximately 7.6% of Seer and intend to solicit votes for director nominees at the 2026 annual meeting using a white universal proxy card.
The group submitted an improved non-binding proposal to acquire 100% of Seer for $2.35 per share in cash plus a contingent value right (CVR) giving stockholders a share of future proceeds from dispositions. The proposal cites a 39% premium to an unaffected closing price and is conditioned on at least $215 million of net cash at closing; it requests a Board response by May 2, 2026.
Seer, Inc. disclosed that it has received a highly contingent, non-binding and unsolicited proposal from the Radoff-JEC Group to acquire all outstanding shares of Seer’s Class A common stock for $2.25 per share in cash plus a contingent value right. The Board, with independent financial and legal advisors, will carefully review the proposal to decide what is in the best interests of the company and its stockholders. In parallel, the Radoff-JEC Group has nominated three director candidates for election at Seer’s 2026 Annual Meeting. Seer’s Corporate Governance and Nominating Committee will evaluate these nominees under the company’s bylaws, and the Board will provide its recommendation in a future definitive proxy statement. The company emphasized that no stockholder action is required at this time and plans to send a BLUE proxy card with its 2026 proxy materials.
Seer, Inc. received an amended Schedule 13D from a group led by Bradley Radoff and Michael Torok outlining an unsolicited takeover proposal and board contest. The group and related entities report beneficial ownership stakes ranging from 0.4% to 4.6% of Seer’s Class A common stock.
On April 13, 2026, the reporting persons submitted a non-binding proposal to acquire 100% of Seer’s equity for $2.25 per share in cash, a stated 33% premium to the most recent closing price, plus a contingent value right giving stockholders 80% of net proceeds from any sale or license of Seer’s business and assets, including PrognomiQ. The proposal assumes at least $215 million of net cash and cash equivalents at closing and is not subject to financing conditions.
The group asked Seer’s board to respond to the proposal by 5:00 p.m. ET on April 22, 2026, after which it would expire. Radoff also nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini to Seer’s board for the 2026 annual meeting and the group entered into an amended and restated group agreement covering joint filings, proxy solicitation efforts and trading restrictions while Seer’s tax benefit preservation plan (the “NOL Pill”) remains in effect.